New Guidelines for GLP-1 Treatment: Balancing Risks of Semaglutide with Tirzepatide's Liver Benefits
PILLAR DIAGNOSTIC // WEEK 38
“While semaglutide is associated with an elevated risk of nonarteritic anterior ischemic optic neuropathy, tirzepatide demonstrates hepatoprotective mechanisms in preclinical models. These observations target different organ systems and are therefore nonconflicting. The overall risk posture is to apply differentiated mitigation strategies: maintain vigilance for ocular complications with semaglutide, and explore tirzepatide’s liver benefits where appropriate.”
Proposed action
Implement routine ophthalmologic assessments and patient education for those receiving semaglutide. Concurrently, initiate clinical studies to validate tirzepatide’s hepatic advantages in humans and consider it for patients at higher risk of liver stress, aligning drug selection with individual risk profiles.
THE MECHANICS
Spread & delivery
—
THE MACHINE
Evidence & systems
Semaglutide use carries an elevated risk of nonarteritic anterior ischemic optic neuropathy (NAION), accounting for 86.5 % of GLP-1 agonist–related cases, while tirzepatide preserves hepatic mitochondrial architecture, downregulates autophagy and mitophagy genes, and mitigates ER stress in a mouse model of obesity, type 2 diabetes, and menopause.
THE MAP
Policy & population
—
THE MOOD
Trust & behavior
—